Sermorelin: The Older GHRH Peptide, Explained

Sermorelin is a growth-hormone-releasing hormone (GHRH) analog made of the first 29 amino acids of human GHRH. It stimulates your own pituitary to release growth hormone (GH) rather than supplying GH directly, and it has a longer clinical and regulatory history than newer peptides: it was previously FDA-approved and is still compounded and prescribed through some clinics. Its evidence for anti-aging and body recomposition is limited, while its older pediatric and diagnostic use is better established. It is not currently FDA-approved and is banned in sport by WADA.

What sermorelin is

Sermorelin is a synthetic fragment of human GHRH, specifically the GHRH 1-29 amide, which is the portion researchers identified as carrying the core biological activity. It is shorter than both native GHRH (44 amino acids) and tesamorelin, and it has a short half-life of roughly 10 to 20 minutes. Because it clears quickly, clinic protocols typically involve frequent dosing, often nightly, which is a real-world adherence consideration.

Mechanistically, sermorelin binds GHRH receptors on the pituitary and prompts the gland to release GH in pulses. This is the defining feature of GHRH analogs: they amplify your body's own pulsatile GH output rather than flooding the system with continuous external GH the way recombinant human GH does. Proponents argue that preserving pulsatility is a theoretical safety advantage, though that has not been definitively validated by long-term human safety data. Our overview of how growth-hormone peptides work explains the GHRH-versus-secretagogue distinction.

The FDA history nuance

Sermorelin's regulatory story is genuinely different from the research peptides it gets grouped with, and the nuance matters.

Sermorelin was FDA-approved, under the brand names Geref Therapeutic for growth-hormone deficiency in children and Geref Diagnostic for GH stimulation testing. The manufacturer, Serono, voluntarily withdrew both products commercially in 2008 for business reasons, market dynamics rather than any safety signal. Because the approved finished products no longer exist, sermorelin is no longer an FDA-approved drug today.

But that prior-approval history leaves a meaningful footprint. It gives sermorelin a documented track record that supports a relatively more favorable compounding-pharmacy position than peptides that were never approved at all, like CJC-1295 or ipamorelin. The FDA has not definitively confirmed compounding eligibility for every formulation, and the broader peptide compounding landscape is in flux in 2026, so the right framing is "more settled than research-only peptides, but still not FDA-approved." Check FDA.gov for current status.

Sermorelin compared to CJC-1295 and tesamorelin

Peptide	Half-life	Approval history	Evidence base
Sermorelin	Short (roughly 10 to 20 minutes)	Previously FDA-approved; withdrawn 2008	Pediatric GH deficiency and diagnostic use established; adult anti-aging limited
CJC-1295 (with DAC)	Long (roughly 6 to 8 days)	Never approved	Small early-phase human data only
Tesamorelin	Intermediate, daily or weekly (Egrifta WR)	FDA-approved for HIV lipodystrophy	Strong RCT data in its indication

This table compares half-life, approval history, and evidence, not doses. Any dosing for sermorelin is set by a prescriber, not chosen from a chart.

The evidence, honestly

Sermorelin's evidence base is better than most peptides in this category but still below modern randomized-trial standards for its popular uses.

The stronger, older evidence sits in its original approved roles: GH stimulation testing and treatment of GH deficiency in children, where it has a documented clinical history. The weaker evidence sits in the uses that drive most current demand. Small human studies show that sermorelin raises GH and IGF-1, but there are no large modern randomized controlled trials demonstrating meaningful anti-aging, sleep, or body-recomposition benefits in adults. So the GH-and-IGF-1 rise is real; the leap to "this will recompose your body or reverse aging" is not established. We cover that hype-versus-evidence gap for the whole class in GH peptides for body recomposition.

It is worth being clear about what "age-related GH decline" does and does not justify. GH output does fall gradually with age, a pattern sometimes called somatopause, and that observation is the marketing hook for adult sermorelin use. But a normal age-related decline is not the same as a diagnosed deficiency, and restoring a hormone toward youthful levels has not been shown to deliver the youthful outcomes people hope for. The honest framing is that sermorelin can nudge a lab value, while whether that nudge produces a benefit you can feel or measure is the part the evidence has not settled.

Sermorelin versus CJC-1295: the practical difference

Because sermorelin and CJC-1295 are the two GHRH analogs people most often compare, the practical distinction is worth spelling out beyond the table. The biggest difference is half-life and how that shapes the GH signal. Sermorelin clears in minutes and produces a short, sharp prompt that more closely mimics the body's own pulsatile GHRH signal. CJC-1295 with DAC lingers for days and produces a more sustained elevation, which proponents frame as convenient but which is arguably less physiologic than a brief pulse.

The second difference is regulatory footing, and it is the one that matters most for real-world use. Sermorelin's prior FDA approval and clinic-prescribed compounding pathway put it on more settled ground, while CJC-1295 was never approved and a US advisory committee voted against it for compounding eligibility in late 2024. For someone trying to use a GHRH analog through a legitimate provider, that difference is not academic. Our CJC-1295 guide covers that compound's status in detail.

Common reported uses, and the off-label line

In current practice, sermorelin is most often prescribed off-label for anti-aging, sleep quality, body recomposition, and GH "optimization" in middle-aged adults with age-related GH decline. All of these are off-label, because there is no current FDA-approved sermorelin product. The difference from research peptides is the pathway: sermorelin typically comes through a licensed prescriber and a compounding pharmacy rather than an unregulated vendor, which generally means better quality control, though it does not make the use approved.

Sleep is one of the more commonly cited reasons people try sermorelin, on the logic that GH is released largely during deep sleep and that supporting the GH axis might improve sleep quality. That mechanism is plausible, and some users report better sleep, but plausibility and anecdote are not the same as trial evidence, and sleep is notoriously susceptible to expectation effects. It is exactly the kind of subjective claim that deserves to be tracked rather than assumed, which is where structured logging earns its place.

It also bears repeating that for athletes, none of these off-label uses are exempt from anti-doping rules. Sermorelin sits on the WADA Prohibited List under category S2 as a GHRH analog, banned at all times, so a clinic prescription does not make it safe to use in tested sport.

Safety and side effects

Sermorelin shares the GH-secretagogue class effects: fluid retention, possible effects on glucose, IGF-1 elevation, and the theoretical concern that raising IGF-1 could stimulate a pre-existing malignancy. Reported side effects also include headache and flushing, and injection-site reactions are possible. Its short half-life means frequent, often nightly, injections, which is less a safety issue than a compliance and lifestyle one.

As with any GH-axis agent, anyone with a cancer history, a pituitary disorder, or significant metabolic risk needs a clinician weighing in before considering it. The point of the prescribed pathway is that a provider monitors IGF-1 and other markers, which is exactly the kind of oversight a self-directed research-peptide routine lacks.

What to ask a provider

Helpful questions for a clinician include: Does my goal have any real evidence behind it for sermorelin, or am I relying on the older pediatric data? How will we monitor IGF-1 and glucose? Does the frequent nightly dosing fit my life well enough to be consistent? And given my history, is a GH-axis agent appropriate at all? A provider experienced in hormonal health can answer these in the context of your labs. For the labs a hormone-focused clinic typically tracks, see our TRT bloodwork guide, which covers overlapping markers.

The tracking angle

A clinic-prescribed sermorelin protocol still needs day-to-day organization, and the nightly dosing makes consistency the whole ballgame. Myo tracks injections, sends reminders so the cadence holds, and logs the body-composition and lab trends your prescriber will want to review at follow-up. If you are reconstituting from powder, the reconstitution calculator handles the concentration math so the dose you record is accurate.

Because sermorelin's claimed benefits are largely subjective, sleep, energy, body composition, the trend matters more than any single day. Myo charts those over weeks and pairs them with the same fat-versus-lean tracking it uses for body composition on a GLP-1, so a provider-directed protocol becomes a reviewable record rather than a hopeful guess. Myo tracks the protocol; it does not recommend or source it.

References

• US FDA. Geref (sermorelin) historical approval and 2008 market withdrawal records. FDA.gov.
• Healthline and Wikipedia summaries of sermorelin mechanism, half-life, and clinical history.
• Published small studies of sermorelin showing GH and IGF-1 increases in adults; absence of large modern RCTs for anti-aging and body-composition endpoints.
• World Anti-Doping Agency. 2026 Prohibited List, category S2 (GHRH analogs). wada-ama.org.